The incremental cost of disease progression among patients with metastatic stage IIIB or IV non-small cell lung cancer versus those without progression was $12,327 for 3 postprogression months.
Kathleen M. Fox, MHS, PhD
Advertisement
Articles by Kathleen M. Fox, MHS, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
2
National HIV Testing Day Highlights Expanding PrEP, PEP Access, Persistent Barriers
3
Treatment Burden, End-of-Life Symptom Gaps in Multiple Myeloma
4
Health Equity & Access Weekly Roundup: June 26, 2026
5